Mika Health has partnered with AstraZeneca and Daiichi Sankyo on an initiative called "UNITE" to provide digital therapeutics for women undergoing breast cancer treatments. Mika Health's app offers cancer patients psychological support, medication tracking, reminders, educational content, nutrition advice, and appointment coordination. This digital therapeutic, already certified in the EU, can be personalized based on the patient's specific cancer type and will be used alongside pharmaceutical therapies.
Initially, the offering will be available to German-speaking patients in Switzerland, with plans to expand to French- and Italian-speaking regions. Adam Nosal of AstraZeneca Switzerland emphasized the importance of digital therapies in modern cancer treatment and the potential to enhance holistic cancer care through this partnership.
In addition, Mika Health has teamed up with the Cancer Support Community to provide AI-enabled digital therapeutics for U.S.-based cancer patients and their caregivers for free. They also partnered with AI oncology firm Massive Bio to offer Mika's services through their platform, including AI-enabled biomarker testing and clinical trial matching.
Click here to read the original news story.